Company Overview
Company Type: Private Company
Website: www.nonoinc.ca
Number of Employees: -
Year Founded: 2003
Total Amount Raised (CAD mm)†: 9.77
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
NoNO Inc., a biotherapeutics company, engages in the research, development, and commercialization of pharmaceuticals for the treatment of common health disorders that include strokes, traumatic brain injuries, and pains. Its NA-1 is a therapeutic used for the treatment of neurological disorders. The company’s products also include TRPM7, an ion channel that reduces ischemic damage in cell culture models of retinal, neuronal, myocardial, liver, and renal ischemia; and SRC-ND2 that reduces inflammatory and neuropathic pain behaviors in animals. NoNO Inc. was incorporated in 2003 and is based in Toronto, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Tymianski, Michael
Chief Executive Officer, President and Director
Salter, Michael W.
Vice President of Finance, Director and Member of Scientific Advisory Board
Garman, David
Chief Operating Officer

Key Board Members
Name
Title
Tymianski, Michael
Chief Executive Officer, President and Director
Salter, Michael W.
Vice President of Finance, Director and Member of Scientific Advisory Board
Gurd, James W.
Member of Scientific Advisory Board
Josephson, Josh
Director
Krembil, Mark 
Director
MacDonald, John F.
Member of Scientific Advisory Board
Tasker, R. Andrew
Member of Scientific Advisory Board
Wang, Yu-Tian
Member of Scientific Advisory Board
Wolfond, Gregory H.
Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
479A Wellington Street West | Toronto, ON | M5V 1E7 | Canada
Phone: 416-603-5801   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
Blue Sky Capital Corporation
-
Unknown
-
-
Gregory Wolfond


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-22-2013
-
Private Placement
Target
NoNO Inc.


9.46
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-15-2020
Company Conference Presentations
NoNO Inc. Presents at TIDES: Oligonucleotide and Peptide Therapeutics, Sep-15-2020
Feb-12-2019
Company Conference Presentations
NoNO Inc. Presents at 21st Annual BIO CEO & Investor Conference 2019, Feb-12-2019 10:45 AM
Jan-08-2019
Company Conference Presentations
NoNO Inc. Presents at Biotech Showcase 2019, Jan-08-2019 02:15 PM
May-09-2018
Company Conference Presentations
NoNO Inc. Presents at TIDES 2018: Oligonucleotide and Peptide Therapeutics, May-09-2018 11:45 AM
Mar-27-2018
Company Conference Presentations
NoNO Inc. Presents at Oligonucleotide & Peptide Therapeutics Boston Conference, Mar-26-2018 through Mar-27-2018


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 15, 2023 09:25 AM
NoNO Inc.
NoNO Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
25
GlobalData

Sep 14, 2023 09:16 PM
NoNO Inc.
NoNO Inc
Reports
33
GlobalData

Jun 15, 2023 06:21 AM
NoNO Inc.
NoNO Inc
Reports
33
GlobalData

Jun 09, 2023 05:35 AM
NoNO Inc.
NoNO Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
25
GlobalData

Mar 14, 2023 01:31 AM
NoNO Inc.
NoNO Inc
Reports
34
GlobalData

Mar 10, 2023 03:49 AM
NoNO Inc.
NoNO Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
25
GlobalData

Dec 13, 2022 05:05 AM
NoNO Inc.
NoNO Inc
Reports
32
GlobalData

Dec 09, 2022 12:53 AM
NoNO Inc.
NoNO Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
25
GlobalData

Sep 22, 2022 05:56 AM
NoNO Inc.
NoNO Inc
Reports
27
GlobalData

Sep 15, 2022 04:27 AM
NoNO Inc.
NoNO Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
25


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Drugs (Future)


Upcoming Events
Date/Time
Type
Nov-07-2023
Company Conference Presentations
Nov-07-2023
Conferences
* Future Events are subject to change.

Key Board Members Details
Name
Title
Phone
Fax
Email
Tymianski, Michael
Chief Executive Officer, President and Director
416-603-5801
-
-
Salter, Michael W.
Vice President of Finance, Director and Member of Scientific Advisory Board
416-603-5801
-
-
Gurd, James W.
Member of Scientific Advisory Board
416-603-5801
-
-
Josephson, Josh
Director
416-603-5801
-
-
Krembil, Mark 
Director
416-861-8391X102
-

MacDonald, John F.
Member of Scientific Advisory Board
416-603-5801
-
-
Tasker, R. Andrew
Member of Scientific Advisory Board
416-603-5801
-
-
Wang, Yu-Tian
Member of Scientific Advisory Board
416-603-5801
-
-
Wolfond, Gregory H.
Director
416-603-5801
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Tymianski, Michael
Chief Executive Officer, President and Director
416-603-5801
-
-
Salter, Michael W.
Vice President of Finance, Director and Member of Scientific Advisory Board
416-603-5801
-
-
Garman, David
Chief Operating Officer
416-603-5801
-
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
